

## Online Material

**Title: Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: An international randomized controlled trial**

eTable 1: Glucocorticoid dosing regimens used in the RITAZAREM trial

eTable 2: Calculation of modified Combined Damage Assessment Score

eTable 3: Line listing of Severe Infections in the RITAZAREM trial

eTable 1: Glucocorticoid dosing regimens used in the RITAZAREM trial

Time	Induction Schedule A (Prednisone/prednisolone 1 mg/kg group)		Induction Schedule B Prednisone/prednisolone 0.5 mg/kg group	
	<60 kg	≥60 kg	<60 kg	≥60 kg
Week 0	50	60	25	30
Week 2	35	45	20	25
Week 4	25	35	17.5	20
Week 6	20	25	15	17.5
Week 8	15	17.5	12.5	15
Week 10	12.5		12.5	
Week 12	10		10	
	<b>Maintenance Schedule: Daily prednisone/prednisolone dose (mg)</b>			
Week 16 (randomization)	10			
Week 18	7.5			
Week 22	5			
Month 16	2.5			
Month 20	0			

eTable 2: Calculation of modified Combined Damage Assessment Score

Category	Items	Maximum score
<b>Musculoskeletal</b>	1 - Significant muscle atrophy or weakness 2 - Deforming/erosive arthritis 3 - Osteoporosis/vertebral collapse 4 - Avascular necrosis 5 - Osteomyelitis	<b>5</b>
<b>Skin / Mucous membranes</b>	1 - Alopecia 2 - Cutaneous ulcers 3 - Mouth ulcers	<b>3</b>
<b>Ocular</b>	1 - Cataract 2 - Retinal changes or Retinal artery occlusion or Retinal vein occlusion 3 - Optical nerve atrophy 4 - Low vision or Diplopia 5 - Blindness in one eye (left or right) 6 - Blindness in second eye (both) 7 - Orbital wall destruction	<b>7</b>
<b>Ear nose and throat (ENT)</b>	1 - Sensorineural hearing loss or Conductive hearing loss 2 - Chronic rhinitis/crusting 3 - Nasal bridge collapse/saddle nose or Nasal septal perforation 4 - Chronic sinusitis 5 - Subglottic stenosis (no surgery) 6 - Subglottic stenosis (surgery)	<b>6</b>
<b>Pulmonary</b>	1 - Pulmonary hypertension 2 - Pulmonary fibrosis 3 - Pulmonary infarction 4 - Pleural fibrosis 5 - Chronic asthma 6 - Chronic breathlessness 7 - Irreversible loss of lung function	<b>7</b>
<b>Cardiac</b>	1 - Angina or Percutaneous coronary intervention 2 - Myocardial infarction 3 - Coronary artery bypass graft 4 - Cardiomyopathy (NYHA Class I/II or NYHA class III/IV) 5 - Valvular Disease 6 - Pericarditis or Pericardectomy 7 - Hypertension	<b>7</b>
<b>Vascular</b>	1 - Absent pulses in 1 limb 2 - 2nd episode of absent pulses in 1 limb 3 - Major vessel stenosis 4 - Claudication > 3 months 5 - Minor tissue loss 6 - Major tissue loss 7 - Subsequent major tissue loss 8 - Deep venous thrombosis or Complicated venous thrombosis	<b>8</b>
<b>Gastrointestinal</b>	1 - Gut infarction/resection 2 - Mesenteric insufficiency/pancreatitis 3 - Esophageal stricture/surgery 4 - Chronic peritonitis	<b>4</b>

Category	Items	Maximum score
Renal	1 - Estimated/measured GFR<50% 2 - Proteinuria (any item) 3 - End-stage renal disease or Dialysis	3
Neuropsychiatric	1 - Cognitive impairment 2 - Major psychosis 3 - Seizures 4 - Cerebrovascular accident 5 - 2nd cerebrovascular accident 6 - Cranial nerve lesion 7 - Sensory polyneuropathy or Motor Neuropathy 8 - Transverse myelitis	8
Other	1 - Gonadal failure (Premature ovarian failure or Azoospermia) 2 - Marrow failure (Refractory cytopenia or Myelodysplastic syndrome) 3 - Diabetes mellitus 4 - Chemical cystitis 5 - Malignancy 6 - Other	6
<b>TOTAL</b>		<b>64</b>

eTable 3: Line listing of Severe Infections in the RITAZAREM trial

Infection type	Subjects			Non-Randomized	Events Total
	Total	Azathioprine	Rituximab		
<b>TOTAL</b>	<b>39</b>	<b>19</b>	<b>15</b>	<b>5</b>	<b>54</b>
Appendicitis	3	1	2	0	3
Bronchitis	3	2	1	0	3
Cellulitis	1	1	0	0	1
Dacryocystitis	1	1	0	0	1
Diverticulitis	1	1	0	0	2
Gastroenteritis viral	1	1	0	0	1
Influenza	5	3	2	0	5
Lower respiratory tract infection	2	2	0	0	2
Peritonitis	1	1	0	0	2
Pneumonia	10	3	5	2	11
Pneumonia klebsiella	1	1	0	0	1
Pneumonia streptococcal	1	0	0	1	1
Pneumonia viral	1	0	1	0	1
Progressive multifocal leukoencephalopathy	1	0	0	1	1
Sepsis	2	0	2	0	2
Sinusitis	1	0	1	0	1
Urinary tract infection	3	2	1	0	3
Escherichia urinary tract infection	2	0	1	1	2
Periorbital abscess	1	0	1	0	1
Infective exacerbation of chronic obstructive airways disease	2	1	0	1	2
Pseudomonas infection	1	0	0	1	1
Respiratory tract infection	4	3	1	0	4
Metapneumovirus infection	1	0	1	0	1
Oral herpes	1	1	0	0	1
Systemic viral infection	1	0	0	1	1